<?xml version="1.0" encoding="UTF-8"?>
<html>
   <head/>
   <body>
      <div class="hl7Message">
         <p>MSH|^~\&amp;#|NIST EHR^2.16.840.1.113883.3.72.5.22^ISO|NIST EHR Facility^2.16.840.1.113883.3.72.5.23^ISO|NIST Test Lab APP^<br/>2.16.840.1.113883.3.72.5.20^ISO|NIST Lab Facility^2.16.840.1.113883.3.72.5.21^ISO|20130211184101-0500||OML^O21^OML_O21|N<br/>IST-LOI_8.0_1.1-GU|T|2.5.1|||AL|AL|||||LOI_Common_Component^LOI Base Profile^2.16.840.1.113883.9.66^ISO~LOI_GU_Component<br/>^LOI GU Profile^2.16.840.1.113883.9.78^ISO~LAB_PRU_Component^LOI PRU Profile^2.16.840.1.113883.9.82^ISO<br/>
         </p>
         <p>PID|1||PATID5678^^^NIST MPI&amp;2.16.840.1.113883.3.72.5.30.2&amp;ISO^MR||Vannatatu^Yolanda^G.^^^^L||19281011|F||2076-8^Native <br/>Hawaiian or Other Pacific Islander^HL70005|15006 Bloomquist Way^Apt 4^Huntington Park^CA^90255^^H|||||||||||H^Hispanic^H<br/>L70189<br/>
         </p>
         <p>ORC|NW|ORD798642-1^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||ORD798642^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||||<br/>|20130124|||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.113883.4.6&amp;ISO^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has <br/>been informed of responsibility, and agrees to pay for service^HL70339<br/>
         </p>
         <p>OBR|1|ORD798642-1^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||24323-8^Comprehensive metabolic 2000 panel - Serum or Pla<br/>sma^LN^^^^2.42^^Comprehensive Metabolic profile|||201301240820-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.<br/>113883.4.6&amp;ISO^L^^^NPI|^^PH^^^626^9876543^1<br/>
         </p>
         <p>DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||<br/>||2<br/>
         </p>
         <p>DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2<br/>
         </p>
         <p>DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3<br/>
         </p>
         <p>SPM|1|SP798642-1&amp;Lamaze EHR&amp;2.16.840.1.113883.3.72.7.83&amp;ISO||119364003^Serum specimen (specimen)^SCT^SER^Serum^L|||||||<br/>||||||201301240820-0800<br/>
         </p>
         <p>ORC|NW|ORD798642-2^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||ORD798642^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||||<br/>|20130124|||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.113883.4.6&amp;ISO^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has <br/>been informed of responsibility, and agrees to pay for service^HL70339<br/>
         </p>
         <p>OBR|2|ORD798642-2^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||57021-8^CBC W Auto Differential panel in Blood^LN^^^^2.42<br/>^^CBC W Auto Differential panel in Blood|||201301240825-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.113883.<br/>4.6&amp;ISO^L^^^NPI|^^PH^^^626^9876543^1<br/>
         </p>
         <p>DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||<br/>||2<br/>
         </p>
         <p>DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2<br/>
         </p>
         <p>DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3<br/>
         </p>
         <p>SPM|1|SP798642-2&amp;Lamaze EHR&amp;2.16.840.1.113883.3.72.7.83&amp;ISO||119297000^Blood Specimen^SCT^BLD^Blood^L|||||||||||||20130<br/>1240825-0800<br/>
         </p>
         <p>ORC|NW|ORD798642-3^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||ORD798642^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||||<br/>|20130124|||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.113883.4.6&amp;ISO^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has <br/>been informed of responsibility, and agrees to pay for service^HL70339<br/>
         </p>
         <p>OBR|3|ORD798642-3^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||59261-8^Hemoglobin A1c/Hemoglobin.total in Blood^LN^^^^2.<br/>42^^Hemoglobin A1c NGSP protocol in blood|||201301240825-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.113883<br/>.4.6&amp;ISO^L^^^NPI|^^PH^^^626^9876543^1<br/>
         </p>
         <p>DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||<br/>||2<br/>
         </p>
         <p>DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2<br/>
         </p>
         <p>DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3<br/>
         </p>
         <p>SPM|1|SP798642-2&amp;Lamaze EHR&amp;2.16.840.1.113883.3.72.7.83&amp;ISO||119297000^Blood Specimen^SCT^BLD^Blood^L|||||||||||||20130<br/>1240825-0800<br/>
         </p>
         <p>ORC|NW|ORD798642-4^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||ORD798642^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||||<br/>|20130124|||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.113883.4.6&amp;ISO^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has <br/>been informed of responsibility, and agrees to pay for service^HL70339<br/>
         </p>
         <p>OBR|4|ORD798642-4^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||1554-5^Glucose [Mass/volume] in Serum or Plasma --12 hour<br/>s fasting^LN^^^^2.42^^Glucose 12 hr fasting|||201301240820-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.1138<br/>83.4.6&amp;ISO^L^^^NPI|^^PH^^^626^9876543^1<br/>
         </p>
         <p>DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||<br/>||2<br/>
         </p>
         <p>DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2<br/>
         </p>
         <p>DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3<br/>
         </p>
         <p>OBX|1|CWE|49541-6^Fasting status^LN^1902^Fasting Status^99USL||Y^Yes^HL70136||||||O|||20130124|||||||||||||||SCI<br/>
         </p>
         <p>SPM|1|SP798642-1&amp;Lamaze EHR&amp;2.16.840.1.113883.3.72.7.83&amp;ISO||119364003^Serum specimen (specimen)^SCT^SER^Serum^L|||||||<br/>||||||201301240820-0800<br/>
         </p>
         <p>ORC|NW|ORD798642-5^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||ORD798642^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||||<br/>|20130124|||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.113883.4.6&amp;ISO^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has <br/>been informed of responsibility, and agrees to pay for service^HL70339<br/>
         </p>
         <p>OBR|5|ORD798642-5^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||24331-1^Lipid 1996 panel in Serum or Plasma^LN^^^^2.42^^L<br/>ipid 1996 panel in Serum or Plasma|||201301240825-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.113883.4.6&amp;IS<br/>O^L^^^NPI|^^PH^^^626^9876543^1<br/>
         </p>
         <p>DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||<br/>||2<br/>
         </p>
         <p>DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2<br/>
         </p>
         <p>DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3<br/>
         </p>
         <p>OBX|1|CWE|49541-6^Fasting status^LN^1902^Fasting Status^99USL||Y^Yes^HL70136||||||O|||20130124|||||||||||||||SCI<br/>
         </p>
         <p>SPM|1|SP798642-2&amp;Lamaze EHR&amp;2.16.840.1.113883.3.72.7.83&amp;ISO||119297000^Blood Specimen^SCT^BLD^Blood^L|||||||||||||20130<br/>1240825-0800<br/>
         </p>
         <p>ORC|NW|ORD798642-6^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||ORD798642^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||||<br/>|20130124|||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.113883.4.6&amp;ISO^L^^^NPI||^^PH^^^626^9876543^1||||||2^Patient has <br/>been informed of responsibility, and agrees to pay for service^HL70339<br/>
         </p>
         <p>OBR|6|ORD798642-6^Lamaze EHR^2.16.840.1.113883.3.72.7.83^ISO||50564-4^Urinalysis panel - Urine by Auto^LN^^^^2.42^^Comp<br/>lete UA - Auto|||201301240840-0800|||||||||1238998979^Lamaze^Jerry^^^^^^NPI&amp;2.16.840.1.113883.4.6&amp;ISO^L^^^NPI|^^PH^^^626<br/>^9876543^1<br/>
         </p>
         <p>DG1|1||E11.69^Type 2 diabetes mellitus with other specified complication^I10C^^^^^^Diabetes mellitus type II|||F|||||||<br/>||2<br/>
         </p>
         <p>DG1|2||E78.5^Hyperlipidemia, unspecified^I10C^^^^^^Hyperlipidemia NOS|||F|||||||||2<br/>
         </p>
         <p>DG1|3||I10^Essential (primary) hypertension^I10C^^^^^^Hypertension, NOS|||F|||||||||3<br/>
         </p>
         <p>SPM|1|SP798642-3&amp;Lamaze EHR&amp;2.16.840.1.113883.3.72.7.83&amp;ISO||258574006^Midstream Urine^SCT^URMS^Urine, midstream^L|||||<br/>||||||||201301240840-0800<br/>
         </p>
      </div>
   </body>
</html>